
A new analysis of Public Health England figures by the Local Government Association (LGA) has revealed that one in 25 …

AB Science has U-turned on its pursuit of a do-over on its marketing application of masitinib in Europe after the …

Roche has lifted the curtain on new Phase 3 data for its anti-PD-L1 cancer immunotherapy Tecentriq (atezolizumab), showing that the …

The FDA has expanded the label for UCB’s Cimzia (certolizumab pegol) in the US, approving the therapy for the treatment …

It’s a special Firday here in Europe, as today marks the advent of the General Data Protection Regulation (GDPR), an …

BioMarin is confident that its newly approved treatment for phenylketonuria (PKU) is set to become a blockbuster and it’s priced the …

AstraZeneca and its global biologics R&D MedImmune have lifted the curtain on new Phase 3 data for their immunotherapy Imfinzi …

The news broke at the start of the month that a number of women who should have been invited to …

Prothena Therapeutics has acted drastically by slashing staff numbers by more than half, after the failure of two pivotal trials …

The FDA has put its foot down on over-the-counter teething products for infants and children which contain benzocaine, a pain …

Pharmafocus spoke to John Crowley, CEO of Amicus Therapeutics, about his highly unusual career in the pharmaceutical and biotech industries.

Astellas, under the direction of new CEO, Kenji Yasukawa, has unveiled a major new restructure, ahead of a difficult looking …

The European Commission has given its approval to Sandoz, Novartis’ generics and biosimilars unit, for its biosimilar version of Janssen’s …

A report published by the Institute for Fiscal Studies (IFS) has stressed that UK funding into the NHS needs to …

MSD Keytruda has enjoyed the most success of the PD-1/L1 therapies in clinical trials recently and it’s rapidly cementing its …